Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Accumulated Expenses (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Accumulated Expenses for 6 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 60.93% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, down 60.93% year-over-year, with the annual reading at $1.6 million for FY2025, 60.93% down from the prior year.
  • Accumulated Expenses hit $1.6 million in Q4 2025 for Bolt Biotherapeutics, down from $1.9 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $12.5 million in Q4 2023 to a low of $1.6 million in Q2 2025.
  • Historically, Accumulated Expenses has averaged $6.7 million across 5 years, with a median of $6.4 million in 2024.
  • Biggest five-year swings in Accumulated Expenses: soared 463.99% in 2022 and later tumbled 83.64% in 2025.
  • Year by year, Accumulated Expenses stood at $12.4 million in 2021, then dropped by 24.31% to $9.4 million in 2022, then surged by 33.21% to $12.5 million in 2023, then tumbled by 66.34% to $4.2 million in 2024, then crashed by 60.93% to $1.6 million in 2025.
  • Business Quant data shows Accumulated Expenses for BOLT at $1.6 million in Q4 2025, $1.9 million in Q3 2025, and $1.6 million in Q2 2025.